First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied
BEERSE, BELGIUM , Oct. 15, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalised myasthenia gravis (gMG). Study participants who were treated with nipocalimab plus standard of care (SOC) achieved sustained disease control as measured by the primary endpoint of immunoglobulin G (IgG) reduction from baseline over 24 weeks, and secondary endpoints of improvement in MG-ADLb and QMGc scores.1 These Phase 2/3 data will be featured in an oral presentation (Abstract #MG100) at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place in Savannah, Georgia from October 15 to October 18, where Johnson & Johnson will present 25 abstracts.1,2
“Findings from the Vibrance-MG study underscore the potential of this investigational therapy for young individuals aged 12 – 17 living with gMG. Results show a significant reduction in IgG of approximately 70 percent in adolescents and a clinical benefit that is consistent with the Vivacity-MG3 study in adults,” said Jonathan Strober, Director of the Pediatric Neuromuscular Clinic sponsored in part by the Muscular Dystrophy Association at UCSF Benioff Children’s Hospital.d “It is encouraging to see these positive results as there are currently limited approved advanced treatment options for this adolescent population in Europe.”
About 10 percent of new cases of myasthenia gravis are diagnosed in adolescents (12 – 17 years of age) and the severity of gMG in paediatric patients is heightened with 43 percent having experienced over five hospitalisations in their lifetime, 46 percent having at least one intensive care unit stay and 68 percent having periods of exacerbated disease.3,4,5,6
Treatment with nipocalimab plus SOC met the study’s primary endpoint of reduction in total serum IgG (-69 percent), and the two secondary endpoints of MG-ADL and QMG, which are measures of disease activity.1,e Four of five patients achieved minimum symptom expression (MG-ADL score 0-1) by the end of their treatment phase.1,f,g Nipocalimab was well-tolerated over the six-month period, similar to tolerability seen in adult participants in the Vivacity-MG3 study.1 There were no serious adverse events and no discontinuations due to an adverse event.1
Presented for the first time, these open-label Phase 2/3 results in adolescents are consistent with findings from the pivotal study of nipocalimab in adult patients with gMG.1,7 Nipocalimab when added to SOC is the first FcRn blocker to demonstrate sustained disease control in a registrational trial as measured by improvement in MG-ADL over placebo plus SOC over a period of six months of consistent dosing (Q2 week) among adults living with gMG.7,8
“The Vibrance-MG data add to the expanding clinical profile of nipocalimab and highlight its potential for adolescents living with gMG who are in need of new treatments,” said Sindhu Ramchandren, M.D., Executive Medical Director, Neuroscience, Johnson & Johnson Innovative Medicine. “We are committed to developing innovations for autoantibody-driven neurological diseases, like gMG, with the aim of transforming the lives of people living with these conditions.”
Earlier this year, Johnson & Johnson, announced the submission of applications to the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) seeking approval for nipocalimab for the treatment of gMG.
“At J&J, we are innovating with purpose to lead where medicine is going in the autoantibody diseases space,” said Ludovic de Beaucoudrey, Ph.D., Senior Director, Therapeutic Area Lead, Immunology, Janssen-Cilag Limited, a company of Johnson & Johnson. “We are encouraged by bringing the potential clinical benefit of nipocalimab in adolescents living with generalised myasthenia gravis, and with these promising results, we are one step closer to bringing this innovative treatment option to young people living with this debilitating condition.”
Editor’s notes:
- Patients with positive blood test for acetylcholine receptor (anti-AChR) antibodies or muscle-specific tyrosine kinase (anti-MuSK) antibodies are eligible for the study.1
- MG-ADL (Myasthenia Gravis – Activities of Daily Living) provides a rapid clinical assessment of the patient’s recall of symptoms impacting activities of daily living, with a total score range of 0 to 24; a higher score indicates greater symptom severity.9
- QMG (Quantitative Myasthenia Gravis) is a 13-item assessment by a clinician that quantifies MG disease severity through muscle weakness. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity.10
- Dr Jonathan Strober is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
- Treatment with nipocalimab showed a mean percentage change from baseline to week 24 for total serum IgG of -68.98 percent (standard error [SE] = 7.561).1
- Adolescents who received nipocalimab plus current SOC had a mean baseline score of 4.29 (SE = 2.430) in the MG-ADL scale and a mean baseline score of 12.50 (SE = 3.708) in the QMG scale.1
Adolescents who received nipocalimab plus current SOC had a mean change at week 24 of -2.40 (SE = 0.187) in the MG-ADL scale and -3.80 (SE = 2.683) in the QMG scale.1
About Generalised Myasthenia Gravis (gMG)
Myasthenia gravis (MG) is an autoantibody disease in which the immune system mistakenly makes antibodies (e.g., anti-acetylcholine receptor [AChR], anti-muscle-specific tyrosine kinase [MuSK] or anti-low density lipoprotein-related protein 4 [LRP4]) which target proteins at the neuromuscular junction and can block or disrupt normal signalling from nerves to muscles, thus impairing or preventing muscle contraction.11,12,13 The disease impacts between 56,000 and 123,000 people in Europe and an estimated 700,000 people worldwide.11,14 Approximately 10 to 15 percent of new cases of MG are diagnosed in adolescents (12 – 17 years of age).3,4,5 Among juvenile MG patients, girls are affected more often than boys with over 65 percent of paediatric MG cases in the EU diagnosed in girls.15,16,17,18
Initial disease manifestations are usually ocular but in 85 percent or more cases, the disease generalises (gMG), which is characterised by fluctuating weakness of the skeletal muscles leading to symptoms like limb weakness, drooping eyelids, double vision and difficulties with chewing, swallowing, speech, and breathing.11,19,20,21,22 Vulnerable gMG populations, such as paediatric patients, have more limited therapeutic options.23 Currently, SOC treatments for adolescents with gMG are extrapolated from adult trials.5 Other than symptomatic treatments, there are no approved FcRn blockers that may address the root cause of the disease for adolescents with gMG in Europe.24,25,26,27,28
About the Phase 2/3 Vibrance-MG Study
The Phase 2/3 Vibrance-MG study is an on-going open-label study to determine the effect of nipocalimab in paediatric participants with gMG.29 Seven participants aged 12 – 17 years with a diagnosis of gMG as reflected by a Myasthenia Gravis Foundation of America (MGFA) Class of II through IV at screening, and an insufficient clinical response to ongoing, stable SOC therapy, have been enrolled in the trial.1 Participants must have a positive blood test for either anti-AChR or anti-MUSK autoantibodies.29 The study consists of a screening period of up to four weeks, a 24-week open-label Active Treatment Phase during which participants receive nipocalimab intravenously every two weeks, and a Long-term Extension Phase; a safety follow-up assessment will be conducted at eight weeks after last dose.1,29 The primary outcome of the study is the effect of nipocalimab on total serum IgG, safety and tolerability, and pharmacokinetics in paediatric participants with gMG at 24 weeks.29 Secondary endpoints include change in MG-ADL and QMG scores at 24 weeks.1,29
About Nipocalimab
Nipocalimab is an investigational monoclonal antibody, designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies, potentially without impact on other immune functions.30 This includes autoantibodies and alloantibodies that underlie multiple conditions across three key segments in the autoantibody space including Rare Autoantibody diseases, Maternal Foetal diseases mediated by maternal alloantibodies and Prevalent Rheumatology. 31,32,33,34,35,36,37,38,39 Blockade of IgG binding to FcRn in the placenta is also believed to limit transplacental transfer of maternal alloantibodies to the foetus.40
The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have granted several key designations to nipocalimab including:
- EU EMA Orphan medicinal product designation for HDFN in October 2019
- U.S. FDA Fast Track designation in haemolytic disease of the foetus and newborn (HDFN) and warm autoimmune haemolytic anaemia (wAIHA) in July 2019, gMG in December 2021 and foetal neonatal alloimmune thrombocytopenia (FNAIT) in March 2024
- U.S. FDA Orphan drug status for wAIHA in December 2019, HDFN in June 2020, gMG in February 2021, chronic inflammatory demyelinating polyneuropathy (CIDP) in October 2021 and FNAIT in December 2023
- U.S. FDA Breakthrough Therapy designation for HDFN in February 2024
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at www.innovativemedicine.jnj.com/emea/.
Follow us at www.linkedin.com/jnj-innovative-medicine-emea.
Janssen-Cilag International NV and Janssen-Cilag Limited are both Johnson & Johnson companies.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
# # #
References:
1 Strober J et al. Safety and effectiveness of nipocalimab in adolescent participants in the open label Phase 2/3 Vibrance-MG clinical study. Presentation at American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. October 2024.
2 Johnson & Johnson. Johnson & Johnson showcases innovation and commitment to people living with gMG, presenting 25 abstracts at AANEM Annual Meeting and MGFA Scientific Session. Available at: https://innovativemedicine.jnj.com/newsroom/neuroscience/johnson-johnson-showcases-innovation-and-commitment-to-people-living-with-gmg-presenting-25-abstracts-at-aanem-annual-meeting-and-mgfa-scientific-session Last accessed: October 2024.
3 Evoli A, Batocchi AP, Bartoccioni E, Lino MM, Minisci C, Tonali P. Juvenile myasthenia gravis with prepubertal onset. Neuromuscul Disord. 1998 Dec;8(8):561-7. doi: 10.1016/s0960-8966(98)00077-7.
4 Evoli A. Acquired myasthenia gravis in childhood. Curr Opin Neurol. 2010 Oct;23(5):536-40. doi: 10.1097/WCO.0b013e32833c32af.
5 Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;2011:404101. doi: 10.4061/2011/404101.
6 Barraud C, Desguerre I, Barnerias C, Gitiaux C, Boulay C, Chabrol B. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve. 2018 Apr;57(4):603-609. doi: 10.1002/mus.25965.
7 Antozzi, C et al., Efficacy and Safety of Nipocalimab in patients with Generalized Myasthenia Gravis- Top Line Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 Vivacity-MG3 study. 2024 European Academy of Neurology Congress. June 2024.
8 Johnson & Johnson EMEA. Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad population of myasthenia gravis patients. Available at: https://www.janssen.com/sites/www_janssen_com_emea/files/jj_emea_ean_nipocalimab_press_release_final.pdf. Last accessed: October 2024.
9 Wolfe GI Myasthenia gravis activities of daily living profile. Neurology. 1999;22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487.
10 Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769–72.
11 Chen J, Tian D-C, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. The Lancet Regional Health - Western Pacific. https://www.thelancet.com/action/showPdf?pii=S2666-6065%2820%2930063-8
12 Bacci ED et al. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19(1):335.
13 Wiendl, H., et al., Guideline for the management of myasthenic syndromes. Therapeutic advances in neurological disorders, 16, 17562864231213240. https://doi.org/10.1177/17562864231213240. Last Accessed: October 2024.
14 Bubuioc A, et al. The epidemiology of myasthenia gravis. Journal of Medicine & Life (2021). Jan-Mar;14(1):7-16. doi: 10.25122/jml-2020-0145
15 Popperud TH,et al. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. Eur J Paediatr Neurol. 2017 Sep;21(5):707-714. doi: 10.1016/j.ejpn.2017.04.003.
16 Parr JR, et al. How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child. 2014 Jun;99(6):539-42. doi: 10.1136/archdischild-2013-304788.
17 Truffault F, et al. Comparison of juvenile and adult myasthenia gravis in a French cohort with focus on thymic histology. Sci Rep. 2024 Jun 17;14(1):13955. doi: 10.1038/s41598-024-63162-0.
18 Popperud TH, et al. Juvenile myasthenia gravis in Norway: A nationwide epidemiological study. Eur J Paediatr Neurol. 2017 Mar;21(2):312-317. doi: 10.1016/j.ejpn.2016.09.001.
19 Bever, C.T., Jr, Aquino, A.V., Penn, A.S., Lovelace, R.E. and Rowland, L.P. (1983), Prognosis of ocular myasthenia. Ann Neurol., 14: 516-519. https://doi.org/10.1002/ana.410140504
20 Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003 Feb;60(2):243-8. doi: 10.1001/archneur.60.2.243. PMID: 12580710.
21 Myasthenia gravis fact sheet. Retrieved April 2024 from https://www.ninds.nih.gov/sites/default/files/migrate-documents/myasthenia_gravis_e_march_2020_508c.pdf.
22 Myasthenia Gravis: Treatment & Symptoms. (2021, April 7). Retrieved April 2024 from https://my.clevelandclinic.org/health/diseases/17252-myasthenia-gravis-mg.
23 O’Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. Front Neurol. 2020 Jul 24;11:743. doi: 10.3389/fneur.2020.00743. PMID: 32793107; PMCID: PMC7393473.
24 VYVGART™ SPC. Available at: https://www.ema.europa.eu/en/documents/product-information/vyvgart-epar-product-information_en.pdf. Last accessed: October 2024
25 RYSTIGGO® SPC. Available at: https://www.ema.europa.eu/en/documents/product-information/rystiggo-epar-product-information_en.pdf. Last accessed: October 2024.
26 Zilbrysq ® SPC. Available at: https://www.ema.europa.eu/en/documents/product-information/zilbrysq-epar-product-information_en.pdf. Last accessed: October 2024.
27 Ultomiris. SPC. Available at: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: October 2024.
28 Soliris. SPC. Available at: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: October 2024.
29 ClinicalTrials.gov. NCT05265273. Available at: https://clinicaltrials.gov/study/NCT05265273. Last accessed: October 2024.
30 Ling LE., et al. M281, an anti‐fcrn antibody: Pharmacodynamics, pharmacokinetics, and safety across the full range of IGG reduction in a first‐in‐human study. Clinical Pharmacology & Therapeutics., 2018;105;4:1031–1039. https://doi.org/10.1002/cpt.1276.
31 ClinicalTrials.gov Identifier: NCT04951622. Available at: https://clinicaltrials.gov/ct2/show/NCT04951622. Last accessed: October 2024.
32 ClinicalTrials.gov. NCT03842189. Available at: https://clinicaltrials.gov/ct2/show/NCT03842189. Last accessed: October 2024
33 ClinicalTrials.gov Identifier: NCT05327114. Available at: https://www.clinicaltrials.gov/study/NCT05327114. Last accessed: October 2024
34 ClinicalTrials.gov Identifier: NCT04119050. Available at: https://clinicaltrials.gov/study/NCT04119050. Last accessed: October 2024.
35 ClinicalTrials.gov Identifier: NCT05379634. Available at: https://clinicaltrials.gov/study/NCT05379634. Last accessed: October 2024.
36 ClinicalTrials.gov Identifier: NCT05912517. Available at: https://www.clinicaltrials.gov/study/NCT05912517. Last accessed: October 2024
37 ClinicalTrials.gov Identifier: NCT06028438. Available at: https://clinicaltrials.gov/study/NCT06028438. Last accessed: October 2024.
38 ClinicalTrials.gov Identifier: NCT04968912. Available at: https://clinicaltrials.gov/study/NCT04968912. Last accessed: October 2024.
39 ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: October 2024.
40 Roy S, Nanovskaya T, Patrikeeva S, et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model. Am J Obstet Gynecol. 2019;220(5):498 e491-498 e499.
CP- 481380
October 2024
CONTACT: Media contact: Alexandra Nisipeanu adridean@its.jnj.com +31627142080 Investor contact: Lauren Johnson investor-relations@its.jnj.com
